Total trials
468
Active
99
Phase 3
18
Total enrollment
135,959
Pipeline matrix
Showing 40 of 46 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Risperidone | — | — | — | — | 10 | ||
| aripiprazole | — | — | — | — | 6 | ||
| Clozapine | — | — | — | — | 3 | ||
| Belimumab | — | — | — | — | 2 | ||
| Celecoxib | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 1 | |
| Alteplase | — | — | — | — | — | 1 | |
| Belimumab/Placebo | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | 2 | ||
| FX006 | — | — | — | — | — | 1 | |
| Galantamine Hydrobromide Extended Release | — | — | — | — | — | 1 | |
| Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation | — | — | — | — | — | 1 | |
| Temozolomide and Radiation Alone | — | — | — | — | — | 1 | |
| Intra-arterial Cetuximab | — | — | — | — | — | 2 | |
| Intra-arterial Mannitol | — | — | — | — | — | 2 | |
| Cyclophosphamide | — | — | — | — | 2 | ||
| Bevacizumab | — | — | — | — | 3 | ||
| Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | — | 1 | |
| Bortezomib | — | — | — | — | — | 1 | |
| Lisinopril Pills | — | — | — | — | — | 1 | |
| Benazepril Pill | — | — | — | — | — | 1 | |
| Anakinra 100Mg/0.67Ml Inj Syringe | — | — | — | — | — | 1 | |
| NALIRIFOX | — | — | — | — | — | 1 | |
| Gemcitabine plus nab-Paclitaxel | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Decitabine | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| FEIBA | — | — | — | — | — | 1 | |
| FFP | — | — | — | — | — | 1 | |
| Ergocalciferol 50,000 IU | — | — | — | — | — | 1 | |
| Methimazole | — | — | — | — | — | 1 | |
| Retifanlimab | — | — | — | — | — | 1 | |
| Zanzalintinib | — | — | — | — | — | 1 | |
| Cyclophosphamide, Bortezomib, Abatacept | — | — | — | — | — | 1 | |
| Lidocaine | — | — | — | — | 2 | ||
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Nelitolimod | — | — | — | — | — | 1 |
6 more active programs hidden
Next readouts
- 2023-03-19
- 2024-10-10
- 2025-06-03
- 2025-12-01
- 2026-03-01
- 2026-04-06
- 2026-08
- 2026-10
- 2026-10-01
- 2026-12-31
Top conditions
- Schizophrenia21
- Glioblastoma Multiforme11
- Glioblastoma9
- Bipolar Disorder9
- Stroke9
- Schizoaffective Disorder9
- Brain Cancer8
- GBM7
Frequently asked questions about Northwell Health
- How many clinical trials does Northwell Health have on ClinicalTrials.gov?
- Northwell Health is listed as the lead sponsor on 468 clinical trials in ClinicalTrials.gov, 99 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Northwell Health's trials are in Phase 3?
- 18 of Northwell Health's trials are in Phase 3, spread across 46 active drug programs.
- What therapeutic areas does Northwell Health focus on?
- Northwell Health's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Glioblastoma Multiforme, Glioblastoma, Bipolar Disorder, Stroke.
- When are Northwell Health's next clinical trial readouts?
- Northwell Health has 10 upcoming primary-completion readouts tracked here; the soonest is “Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE”, expected around 2023-03-19.